GlassScriptPhysician profile
Lori Anne Franklin
NPI 1518470491
$2,381.28
in general payments reported to CMS, 2019-2025
16 companies · $836 in 2025
The $836 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $211 · 2023: $649 · 2024: $685 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $428.18 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.84 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $236.26 | 2022-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $228.92 | 2024-2025 | Airsupra, Lokelma |
| Lilly USA, LLC | $224.39 | 2023-2025 | Kisunla, Zepbound, Mounjaro |
| Novo Nordisk INC | $193.44 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Pharmacosmos Therapeutics INC. | $149.49 | 2024 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $124.08 | 2023 | |
| Astellas Pharma US INC | $120.43 | 2024 | Veozah |
| Alcresta Therapeutics, INC. | $110.81 | 2023 | Relizorb |
| Viiv Healthcare Company | $109.23 | 2024 | Apretude |
| Stryker Corporation | $50.84 | 2022 | |
| Coloplast Corp | $49.74 | 2022 | |
| Recordati_rare_diseases_inc. | $49.33 | 2025 | Sylvant |
| Sanofi-Aventis U.S. LLC | $42.59 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $16.71 | 2025 | Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.